Gilead Sciences | GILD - La Marge Brute Sur Les Ventes





La Marge Brute Sur Les Ventes Changement Date
AbbVie USD 14.8B 411M 2026-09
Agios Pharmaceuticals USD 52.86M 11.11M 2026-09
ALKERMES USD 303.36M 71.95M 2026-09
Alnylam Pharmaceuticals USD 930.2M 62.49M 2026-09
Amgen USD 8.46B 1.22B 2026-09
Biogen USD 2.25B 127.8M 2026-09
BioMarin Pharmaceutical USD 719.77M 6.35M 2026-09
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 20.59B 886M 2026-09
Gilead Sciences USD 6.73B 74M 2026-09
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 6.5B 743M 2026-09
Incyte USD 1.45B 120.58M 2026-09
J&J USD 18.55B 6M 2026-09
Merck USD 12.21B 121M 2026-06
Moderna USD 995M 945M 2026-09
Neurocrine Biosciences USD 1.06B 125.3M 2026-09
Novartis USD 11.42B 180M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
PTC Therapeutics USD 321.55M 19.05M 2026-09
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 11.7B 2.99B 2026-09
Sarepta Therapeutics USD 192.12M 59.03M 2026-09
United Therapeutics USD 733.4M 49.6M 2026-09
Vertex Pharmaceuticals USD 2.94B 99.9M 2026-09